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Abstract: Tobacco use is inextricably linked to a number of health risks both in the
general and HIV-infected populations. There is, however, a dearth of research on effective
tobacco control programs among people living with HIV, and especially among adolescents,
young adults and pregnant women, groups with heightened or increased vulnerability
secondary to tobacco use. Adolescents and young adults constitute a growing population of
persons living with HIV infection. Early and continued tobacco use in this population
living with a disease characterized by premature onset multimorbidity and chronic
inflammation is of concern. Additionally, there is an increased acuity for tobacco control
among HIV-infected pregnant women to reduce pregnancy morbidity and improve fetal
outcome. This review will provide an important summary of current knowledge of tobacco
use among HIV-infected adolescents, young adults and pregnant women. The effects of
tobacco use in these specific populations will be presented and the current state of tobacco
control within these populations, assessed.
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1. Introduction
It is estimated that over 1.1 million people are living with HIV/AIDS in the United States [1] of
whom 25% are women and 6% adolescents and young adults aged 13–24 years [2]. In 2009, 20% of
newly diagnosed HIV-infected persons were aged 13–24 years [3]. Among women infected with HIV,
approximately 75% are estimated to be in the reproductive age group (13–44 years) [4]. The mortality
rate associated with HIV infection has significantly declined since the introduction of highly active
antiretroviral therapy (HAART) [5,6], although still remains higher than that of the general population
and life expectancy slightly lower [7–9]. HIV-infected persons in contemporary outpatient care are
more likely to die from non-AIDS-defining illnesses (NADI) such as cardiovascular and cancer-related
deaths, than AIDS-defining illnesses [10,11]. The occurrence of NADIs across all CD4 cell counts and
level of viral suppression [12] suggests that other mechanisms apart from immunosuppression
contribute to this excess mortality. The chronic inflammation associated with HIV infection has been
thought to significantly contribute to the development of NADIs [13–15]. Co-infection with hepatitis C,
viral latency, and microbial gut translocation are some of the conditions that contribute to
HIV-associated persistent inflammation [16]. Regardless, behavioral factors play a fundamental role,
and of those, tobacco use may be among the most important.
At present, tobacco use is the leading cause of preventable mortality and morbidity and premature
death in the United States [17,18]. It is also a major cause of preventable infant mortality and
morbidity in the US and other industrialized countries [19]. Among HIV-uninfected adults, the
prevalence of tobacco use is 19% (Table 1) and more common among those aged 18–44 years, without
a Bachelor’s degree, who are uninsured, and who belong to poorer families [18,20]. The prevalence of
tobacco use is 50–70% in the HIV-infected population, 2–3 times higher than the general
population [21,22] (Table 1), and is also more common among younger persons (median age
35 years) [23] with lower socio-economic status [24].
Table 1. A comparison of the prevalence of tobacco use between HIV-infected and general population.
Groups
Adults
Adolescents/young
adults
Pregnant women

General population
19% [20]
23% [18]
5–36% (over-all 14%) [28]

HIV-infected
50–70% [21,22]
4% (HIV acquired vertically) [25]
39% (HIV acquired behaviorally) [26]
21% (over-all estimate) [27]
40–54% (before 1998) [29,30]
14% (after 1997) [31]

There is now evidence to suggest that the use of tobacco among adolescents and young adults is
associated with development of respiratory and cardiovascular problems that serve as precursors to
more long term and chronic diseases in late adulthood [18]. Thus, the higher prevalence of tobacco use
among HIV-infected adolescents and young adults is alarming as HIV infection, itself, has also been
associated with early-onset multimorbidity [32]. Tobacco use during pregnancy is associated with
significant maternal and fetal morbidity and mortality. Furthermore, tobacco use increases the risk of
vertical transmission of HIV infection, independent of maternal disease status and use of other
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substances [30]. Therefore, there is a critical need to address tobacco use among these vulnerable
HIV-infected groups and to ensure that effective tobacco control strategies are implemented.
At present, the combination of behavioral modification through counseling and pharmacotherapy is
the mainstay of tobacco control programs in the general population [33]. There are a dearth of studies
that support the effectiveness of these well-established strategies among persons living with
HIV/AIDS. In fact, there are currently no studies among HIV-infected adolescents and pregnant
women. The studies among HIV-infected adults that have been published so far have found that these
conventional approaches to tobacco control are suboptimal in the HIV-infected population [34].
HIV-infected persons frequently have additional comorbidities that make tobacco cessation
particularly challenging, including alcohol and illicit drug use and psychological stressors [35]. Failure
to promote an effective tobacco control program in this high risk population is concerning as the
mortality and morbidity benefits of tobacco cessation are undisputable [36]. Among persons living
with HIV/AIDS, cessation of tobacco use was associated with a reduction in the adjusted incidence
rate ratio for the development of cardiovascular disease from 2.32 to 1.49 after only three years of
tobacco abstinence [37]. In the general population, tobacco cessation during pregnancy prevented
5–6% of perinatal deaths, 7–10% of preterm deliveries, and 17–26% of low-birthweight births [36].
In this review, we first examine the epidemiology of tobacco use among both HIV-infected and
uninfected adolescents, young adults and pregnant women. We then review the impact of tobacco use
among HIV-infected persons and discuss different tobacco control strategies that have been studied.
Next we look at the current state of tobacco control among adolescents, young adults and pregnant
women in the general population. Finally, we examine how tobacco control can be addressed among
HIV-infected adolescents, young adults and pregnant women, applying lessons derived from studies in
the HIV-uninfected population.
2. Epidemiology of Tobacco Use among Adolescents and Young Adults
2.1. General Population
Current estimates show that 88% of adult smokers in the US initiate tobacco use before 18 years [38]
and 99% before 26 years [18]. Experimentation with tobacco peaks at age 11 to 13 years among
adolescents and more than one third become regular habitual smokers thereafter [39]. In 2009, 23% of
US high school students were current smokers [18] (Table 1). Among all age groups in the US,
the highest prevalence of tobacco use is among young adults aged 18–25 years with a rate of 34% [18].
In general, these estimates among adolescents and young adults declined from the late 1990’s but the
rate of decline considerably diminished in the last few years. Prevalence has remained highest among
American Indians and Alaskan Natives, and among those with low socioeconomic status [18].
2.2. HIV-Infected Population
At present, there are only a few studies that address the prevalence of tobacco use among
HIV-infected adolescents. The Reaching for Excellence in Adolescent Care and Health Project was a
multicenter collaboration in the US that enrolled both HIV-infected and uninfected adolescents aged
12–18 years from 1996 to 2000 [26]. HIV infection among infected adolescents was acquired through
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high risk behavior (i.e., sexual activity, intravenous drug use) and those with vertically-transmitted
HIV infection were excluded. HIV-uninfected adolescents with similar high risk behaviors were
likewise recruited for comparison. In this cohort of 325 HIV-infected adolescents (26% male, 73%
black), the over-all prevalence of tobacco use was 39% (Table 1), of whom, 27% were daily and 11%
were weekly smokers. Fifty eight percent of HIV-infected males used tobacco (39% daily and 19%
weekly smokers) while only 34% of females smoked (25% daily and 9% weekly smokers).
The over-all prevalence of tobacco use among HIV-uninfected counterparts was also high at 36%.
The rate of tobacco use among males was lower (42%) but among females, the rate was comparable
(34%) to the HIV-infected group.
The prevalence of tobacco use among adolescents with vertically transmitted HIV infection is
generally lower. In a cohort of 206 HIV-infected adolescents aged 9–16 years in New York, 4% used
tobacco (Table 1) compared with 7% of HIV-uninfected adolescents (n = 134) matched by age and
demographics (p = 0.97) [25]. In a recent study of 266 persons aged 2–25 years, with either vertically
or horizontally acquired HIV infection, the over-all prevalence of tobacco use was 21% (68% male,
93% black) [27] (Table 1). Subjects who used tobacco in this study were all between 18–25 years.
Lastly, data demonstrate a median age of 16–18 years at the time of tobacco initiation in the
HIV-infected population [40,41].
3. Epidemiology of Tobacco Use among Pregnant Women
3.1. General Population
The proportion of pregnant women in the general population who uses tobacco varies by state and
ranges from 5% to 36% (over-all prevalence of 14%) [28] (Table 1). These estimates are plagued
by underreporting and nondisclosure when self-report is compared to biochemical markers of tobacco
use [42,43]. Hence, the true prevalence of tobacco use in the pregnant population is expected to be
higher. Similar to adolescents and young adults, the prevalence is higher among younger women aged
<25 years, American Indians and Alaskan Natives, and those with lower socioeconomic status.
Likewise, this estimate has progressively declined in recent years [44].
3.2. HIV-Infected Population
In the US, prevalence estimates for tobacco use among HIV-infected pregnant women have varied
considerably. Estimates from the pre- and early HAART era ranged between 31–54% (Table 1).
A survey of all liveborn deliveries from the New York State Medicaid data from 1988 to 1990
identified a 40% prevalence of tobacco use among HIV-infected women (n = 768) during
pregnancy [30]. Tobacco users were more likely to be white, over the age of 25 years, and
multiparous. In a separate cohort, the Pediatric AIDS Clinical Trials Group Study 185, a multicenter
study conducted from 1993–1997 to investigate the use zidovudine and anti-HIV immunoglobulin in
preventing mother-to-child HIV transmission, a 31% prevalence of tobacco use was observed [45].
On the other hand, the Women and Infants Transmission Study which enrolled a cohort of
634 pregnant women from different centers in the US from 1990 to 1998, documented a 54%
prevalence in their cohort [29].

Int. J. Environ. Res. Public Health 2013, 10

2475

More recent estimates match current prevalence rates in the general population. In Florida, an
administrative data review of all HIV-infected women who delivered between 1998 and 2007
demonstrated a 14% prevalence of tobacco use during pregnancy [31] (Table 1). Univariate analysis
showed that pregnant smokers were more likely to be black, less than 35 years old, unmarried, and
have no high school degree. In the Pediatric HIV/AIDS Cohort Study, an 18% prevalence of tobacco
use was observed among 480 HIV-infected pregnant women enrolled from different centers in the
US [46]. This study also found that self-report of tobacco use had an 86% correlation with meconium
cotinine levels.
It is not known why prevalence estimates of tobacco use are higher during the pre- and
early-HAART era. It likely reflects the downward trend in the prevalence rate seen also in the general
population which is mainly a result of more intensive campaigns against tobacco use during pregnancy
in recent years.
4. Impact of Tobacco Use in the HIV-Infected Population
Tobacco use and HIV infection both lead to increased mortality risk and predispose persons to
developing cardiovascular disease [47,48], ischemic stroke [49,50], peripheral vascular disease [51],
lung cancer [52], cervical cancer [53,54], and osteoporosis [55,56] independent of each other.
Although definitely multifactorial, the pathogenesis of these complications reflects certain mechanisms
shared by both HIV infection and tobacco use (Figure 1).
Figure 1. Through shared pathogenic mechanisms, tobacco use magnifies the independent
association of HIV infection with cardiovascular disease, ischemic stroke, peripheral
vascular disease, cancer, osteoporosis, and increased mortality.

HIV infection is associated with persistent inflammation and immune activation that persist even
after full virologic suppression and CD4 cell count recovery with HAART [57]. Elevated markers of
inflammation and coagulation (i.e., interleukin 6, C-reactive protein, soluble CD14, and D-dimer) are
predictive of higher over-all mortality and cardiovascular events [58,59] and are also believed to

Int. J. Environ. Res. Public Health 2013, 10

2476

contribute to the increased risk for atherosclerosis [60], osteoporosis [61], and cancer [62] among
HIV-infected persons. Similarly, tobacco use also leads to chronic inflammation and platelet and
leucocyte activation that directly facilitate atherogenesis [63], carcinogenesis [64], and development of
osteoporosis. Furthermore, it has been shown that tobacco use heightens HIV-associated immune
activation. Miguez-Burbano et al. demonstrated, on multivariate analysis, that HIV-infected smokers
had demonstrably higher IL-6 levels than HIV-infected nonsmokers after adjusting for gender, use of
HAART, stage of HIV disease and body mass index [65]. Our group also found significant association
between elevated levels of T-cell activation (i.e., CD8+ HLA-DR+ and CD4+ HLA-DR+ T lymphocytes)
and current tobacco use among HIV-infected persons with fully suppressed HIV-RNA for at least
2 years [66].
Tobacco use is directly oncogenic and causes many known malignancies including lung, colorectal,
head and neck, pancreatic, and uterine cancer [67]. Similarly, HIV infection has been demonstrated to
also have some oncogenic potential. Witsuba et al. demonstrated that lung cancers from HIV-infected
persons had significantly more frequent microsatellite alterations compared with sporadic lung cancers
from HIV-uninfected persons [68]. Impaired immune surveillance secondary to HIV-associated
immune dysregulation is also believed to contribute to this enhanced oncogenesis [69].
Tobacco use also poses additional health risks to HIV-infected persons (Table 2). These include
an increased risk for infections such as oral candidiasis [70], genital warts [71], pulmonary
tuberculosis [72] and bacterial pneumonia [70], plus human papilloma virus related-malignancies such
as anal and cervical cancer [73]. Tobacco use has also been associated with decreased health-related
quality of life. Among 585 HIV-infected persons, tobacco use, independent of CD4 count, AIDS
diagnosis, educational level, injection drug use, gender and age, was associated with lower scores for
general health perception, physical functioning, bodily pain, energy, role functioning, and cognitive
functioning in the Medical Outcomes Survey Scale (MOS)-HIV questionnaire [74]. There are also data
that suggest an association with tobacco use and clinical progression of HIV infection (i.e., decline in
CD4 count, virologic failure, occurrence of opportunistic infections), however, this finding is not
duplicated by other studies [75].
Table 2. Other effects of tobacco use in the HIV-infected population.
1. Increases risk for certain infections:
a. Periodontal disease [76]
b. Hairy cell leukoplakia [70,77]
c. Oral candidiasis [70,78]
d. Warts [79]
e. Genital warts [71]
f. Tuberculosis [72]
g. Non-tuberculous mycobacteria [80]
2. Increases risk for certain pulmonary diseases
a. Bacterial pneumonia [70,78,81]
b. Spontaneous pneumothorax [82,83]
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3. Increases risk for certain malignancies
a. Cervical cancer [84]
b. Anal cancer [73]
4. Associated with increased risk of certain neuro-psychiatric symptoms
a. Depression [85]
b. AIDS Dementia Complex [78]
5. Associated with over-all decreased quality of life [74,86]
4.1. Impact of Tobacco Use HIV-Infected Adolescents and Young Adults
In the general population, the disease risks associated with tobacco use among adolescents and
young adults are similar to those in older persons. Current evidence suggests that the cardiovascular
and respiratory risks associated with tobacco use are established early among adolescent smokers and
serve as precursors to more chronic and serious problems later in adulthood [18]. Tobacco use among
adolescents and young adults has been directly linked to subclinical atherosclerosis and increased
carotid intimal thickness [87,88] as well as to early markers of vascular endothelial injury [89].
It has also been directly associated with decreased forced expiratory volume [90] and has been shown
to be an independent predictor of asthma, respiratory symptoms such shortness of breath and
wheezing, and decreased exercise tolerance among adolescent smokers [91]. Since these health risks
accumulate over time, it is expected that tobacco use established at an early age is associated with
more adverse outcomes.
Tobacco use also serves as a harbinger for other high risk behaviors. For example, adolescents who
use tobacco are eight and 22 times more likely to use alcohol and cocaine, respectively, and are more
likely to engage in other risky behaviors such as unprotected sexual intercourse, and unhealthy dieting
techniques (i.e., ingesting dietary supplements, not eating for ≥24 h) [92,93]. Among adolescents with
vertically-transmitted HIV infection, smokers were significantly more likely to engage in high risk
sexual behavior including having multiple sexual partners and unprotected vaginal and anal intercourse
compared to nonsmokers [25].
4.2. Impact of Tobacco Use among HIV-Infected Pregnant Women
Tobacco use during pregnancy is associated with preeclampsia, small for gestational age and low
birth weight neonates, spontaneous pregnancy loss, stillbirth, preterm delivery, premature rupture of
membranes, placenta previa, placental abruption, and congenital malformation [94]. In addition,
tobacco use during and after pregnancy has been strongly associated with sudden infant death syndrome
even after adjusting for multiple covariates including race, maternal age and parity [95]. At present,
tobacco use during pregnancy is one of the leading causes of preventable infant mortality and
morbidity in the US and other industrialized countries [19] and tobacco cessation during pregnancy is
one of the strategies employed to curb infant mortality rates in these countries [96]. Maternal HIV
infection has also been associated with adverse pregnancy outcomes including low birth weight,
preterm birth, and intrauterine growth retardation independent of other behavioral risk factors [45].
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With improved understanding of mother-to-child transmission of HIV infection, timely initiation of
antiretroviral drugs, increased Caesarian delivery, and avoidance of breastfeeding when appropriate
among infants exposed to mothers with HIV infection, vertical transmission rate has declined to only
less than 2% [97] in industrialized countries, compared to around 25–30% without these interventions [98].
There are, however, studies that link tobacco use during pregnancy with increased mother-to-child
transmission of HIV infection. Using vital statistics birth data from the New York State Medicaid
HIV/AIDS Research Database, Turner et al. demonstrated among 768 HIV-infected pregnant women
(42% white Hispanic, 41% black) a 45% increase in vertical transmission associated with the use of
tobacco after adjustment for multiple risk factors that included illicit drug use, maternal clinical status,
and delivery factors [30]. This risk may be attributed to higher incidence of premature rupture of
membranes as well as to placental ischemia associated with tobacco use [99].
5. Tobacco Control in the HIV-Infected Population
The factors that negatively influence tobacco control in the general population include low
socioeconomic status [100], existing psychiatric illness [101], and history of substance abuse [102].
Among people living with HIV/AIDS, these factors are more prevalent and often co-exist [24] and
tobacco control has been a real challenge in this population. In a study of 184 HIV-infected tobacco
users in San Francisco (82% male, 53% white), about two-thirds were unemployed and almost half had
an annual income of below $10,000 [103]. In another study in the US, nearly half of 2,864 HIV-infected
persons surveyed had at least one psychiatric disorder [104]. Among over 500 HIV-infected persons in
our institution, approximately 25% had depressive or anxiety symptoms [105,106]. Furthermore,
Cofrancesco et al. reported significantly higher rates of previous (86% versus 67%) and current
(28% versus 16%) substance use among people living with HIV/AIDS compared with uninfected
counterparts [107].
In a review of literature related to tobacco use and HIV/AIDS published from 1980 to 2008, Harris
only found 6 studies on tobacco control interventions. The vast majority (88%) characterized the
impact of tobacco use among people with HIV/AIDS [108]. This paper highlighted the exigency of
conducting studies that aim to determine the best strategy to promote tobacco cessation in the
HIV-infected population.
We independently reviewed PUBMED and found 12 studies, published since 2000, that evaluated
different tobacco cessation strategies (Table 3). The majority of the studies were small and
nonrandomized. All randomized controlled trials compared conventional tobacco cessation practices
(i.e., nicotine replacement therapy (NRT), provision of self-help materials or brief health care provider
advice) with either cellular phone counseling (two studies), motivational intervention (three studies),
or facilitated group treatment (one study). The abstinence rate was only significantly higher in the
cellular phone counseling groups compared to control. There are only three studies, all small,
nonrandomized and non-controlled, which have examined the effectiveness of newer
pharmacotherapeutic agents, buproprion (one study) and varenicline (two studies), in the HIV-infected
population. The results of these three studies were promising as the abstinence rate and medication
adverse effect profile closely approximated those in the general population [109–112].
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Table 3. Studies on tobacco cessation in the HIV-infected population.
Author

Year

Design

Intervention

Wewers [113]

2000

Non-randomized

NRT, weekly in-person or
telephone counseling, skills
training versus self-help
materials

Lazev [114]

2003

Non-randomized

Cellular phone counseling

Vidrine [40]

2006

Randomized

Elzi [115]

2006

Non-randomized

Cellular phone counseling plus
usual care versus usual care
(brief doctor advice, self-help
materials, NRT)
Counseling, NRT vs. no
intervention

Pedro-Clotet [116]

2006

Non-randomized

Buproprion

Ingersoll [117]

2009

Randomized

Motivational intervention plus
NRT versus NRT plus self-help

Lloyd-Richardson
[118]

2009

Randomized

Motivational intervention plus
NRT vs. NRT plus usual care (2
brief counseling sessions and
self-help materials)

Number of
Subjects
Intervention: 8
Control: not stated

Follow-up

Abstinence Rate

6 weeks and 8
months

Intervention: 62% at 6
weeks; 50% at 8 months
Control: 0% 6 weeks; 0% at
8 months
P value not provided
75%

Measure of
Abstinence
Biochemical

Intervention: 20
No control
Intervention: 48
Control: 47

2 weeks
3 months

Intervention: 37%
Control: 10%
P = 0.0059

Biochemical

Intervention: 34
Control: 383

12 months

Self-report

Intervention: 21
No control
Intervention: 18
Control: 22

12 months

Intervention: 232
Control: 212

6 months

Intervention: 38%
Control: 7%
Odds ratio: 6.2
(CI: 2.8–14.3)
Intervention: 38%; no
significant drug interactions
Intervention: 22%, no
difference from the control;
but reduced cigarette
consumption by ½ per day
and percent of smoking days
by 41%
Intervention: 9%
Control: 10%
Not statistically significant

3 months

Self-report

Self-report
Biochemical

Biochemical
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Author

Year

Design

Intervention

Tornero [119]

2009

Non-randomized

Varenicline

Vidrine [41]

2012

Randomized

Moadel [120]

2012

Randomized

Cui [121]

2012

Non-randomized

Cellular phone counseling plus
usual care vs. usual care (NRT,
self-help materials, brief advice
from provider)
Facilitated group treatment plus
NRT vs. usual care (NRT and
self-help materials)
Varenicline

Manuel [122]

2012

Randomized

Motivational intervention plus
NRT versus prescribed advise
(self-help materials discussed
with therapist) plus NRT

Number of
Subjects
Intervention: 22
No control

Follow-up
6 months

Intervention: 236
Control: 238

3 months

Intervention: 73
Control: 72

3 months

Intervention: 36
No control

12 weeks

Intervention: 15
Control: 15

1 month

NRT–nicotine replacement therapy; CI–confidence interval.

Abstinence Rate
Intervention: 24%; adverse
events and abstinence rate
comparable in the general
population
Intervention: 9%
Control: 2%
P = 0.005
Intervention: 19%
Control: 10%
P = 0.11
Intervention: 42%; adverse
events and abstinence rate
comparable in the general
population
Intervention: 20%
Control: 0%
P = 0.067

Measure of
Abstinence
Biochemical

Biochemical

Biochemical

Biochemical

Biochemical
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A few conjectures can be derived from Table 3. First, the combination of tobacco cessation
counseling (in person or by telephone) and use of NRT is still effective among HIV-infected tobacco
smokers [113,115]. Other proposed strategies (i.e., motivational interview, facilitated group treatment)
have not been found to add additional benefits compared to this usual approach. Second, the use of
buproprion and varenicline is expected to yield similar abstinence rates with that in the general
population. However, randomized controlled trials involving these newer pharmacotherapeutic agents
are needed.
6. Tobacco Control among Adolescents in the General Population
Adolescent and adult smokers share some common barriers to tobacco cessation including nicotine
dependence and depression. However, adolescent smokers also have some barriers to tobacco
cessation that may be more influential to them than to adults. Parental smoking negatively influences
smoking behavior among adolescents. A survey of 4,502 adolescents who lived in two-parent
households showed that adolescents whose parents stopped smoking were one third less likely to be
ever smokers than those whose parents were still smoking and that adolescent smokers were two times
more likely to quit smoking if they had parents who quit [123]. Peer influence has also been
demonstrated to greatly impact smoking behavior among adolescents. Transition to daily tobacco use
by the 12th grade at school among 270 adolescents was associated with tobacco use among parents and
close peers on multivariate analysis in one study [124]. Another study demonstrated that among
adolescents who initiated smoking at an older age (13–14 years), tobacco use among peers was the
major influence in contrast to those who initiated tobacco use at a much earlier age (11–12 years)
where parental smoking was found to be more influential [125].
The strategies for tobacco control among adolescents and adults differ in some ways.
Adolescent tobacco control programs rely heavily on addressing psychosocial factors that influence
tobacco use among the youth. Thus, some programs are carried out with the participation of parents,
schools and communities. Furthermore, adolescent tobacco control programs rely less on the use of
pharmacotherapeutic agents like NRT [126].
The main strategy for tobacco control among adolescents has been counseling. Compared to usual
care (i.e., brief advice, self-help pamphlets) or no intervention, physician-delivered counseling is
associated with a two-fold higher abstinence rate [126]. Despite this, it is estimated that only 42–55%
of adolescents are counseled against tobacco use during clinic visits [127,128]. A meta-analysis found
that five to eight counseling sessions were associated with significantly higher abstinence rates
compared with control (5% increase). Nine or more counseling sessions did not increase this
abstinence rate further [129].
Counseling facilitated in schools and other community settings by teachers, nurses, healthcare
counselors and other volunteers, as exemplified by the Not-On-Tobacco (N-O-T) program sponsored
by the American Lung Association [130], has been shown to be effective in promoting tobacco
abstinence based on pooled data from four studies on N-O-T (odds ratio 1.77, 95% CI 1–3.11) [131].
A meta-analysis done by Sussman showed 4–5% higher abstinence rates associated with classroom
and school-based counseling compared with controls [129].
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Similar to the general adult population, a variety of theoretical models have been utilized in tobacco
control counseling whether in the clinic, school, or community, including the transtheoretical model,
motivational enhancement, cognitive behavioral therapy, and social-influence-oriented approach
(Table 4). These models are frequently combined in tobacco control programs. A recent meta-analysis
of 24 randomized controlled trials, comprising a total of 5,000 patients, showed superiority of the
transtheoretical model (two studies analyzed) and motivational enhancement (11 studies analyzed) in
achieving tobacco abstinence of at least six months (each with odds ratio of 1.7) [131]. Cognitive
behavioral therapy (six studies analyzed), in this meta-analysis was not associated with a statistically
significant result. This is in contrast with Sussman’s earlier meta-analysis [129] that showed cognitive
behavioral therapy (17 studies analyzed) was associated with a statistically significant treatment effect
of 3.9%. This study also showed that social-influence-oriented approach was also associated with a
significantly higher abstinence rate compared with usual care.
Table 4. Theoretical models used in smoking cessation counseling.
Counseling models

Theory
Smokers are classified in different stages: precontemplation (not intending to
quit), contemplation (intending to quit within the next 6 months), preparation
Transtheoretical model
(intending to quit within the next 30 days), and recent action (tobacco cessation).
of change [132,133]
Tobacco cessation counseling is then tailored based on this. Providers help
smokers advance to the next stage until they ultimately quit.
Advantages and disadvantages of tobacco use/cessation are determined together
Motivational
with smokers’ beliefs and values in order to identify any uncertainties that
enhancement [126,134] smokers may have. These uncertainties are then focused on and smokers are then
guided in making a detailed quit plan.
Detailed instructions on cognitive-behavioral self-monitoring and coping skills
Cognitive behavioral
regarding tobacco cessation are given (i.e., reasons for tobacco use are
therapy [129]
determined and smokers are taught coping skills)
Strategies aimed at resisting social influences promoting tobacco use are
Social-influenceemphasized (i.e., awareness of tobacco industry promotions and empowerment of
oriented approach [129]
teenagers to protest against them)

Among adolescents, signs and symptoms of nicotine dependence develop first and herald the onset
of tobacco addiction [135]. Adolescents also have a higher risk of becoming nicotine dependent
compared with adults [18]. NRT’s are safe and well-tolerated by adolescents however, a number of
studies have not found its use to be beneficial in this population. Moolchan et al. [136], compared
NRT plus behavioral therapy with behavioral therapy alone among 120 adolescent smokers and found
no statistically significant difference in abstinence rate at three months after study completion in either
arm. Similarly, 30-day tobacco abstinence rate was comparable among 100 adolescent smokers
assigned randomly to receive either NRT plus cognitive behavioral therapy versus cognitive behavioral
therapy alone [137]. A recent meta-analysis by Grimshaw et al. [131], found no pooled treatment
effect associated with the use of NRT in adolescents. For this reason, the Agency for Healthcare
Research and Quality (AHRQ) does not recommend the use of NRT to be part of routine tobacco
control programs among adolescents [126].
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Likewise, the use of buproprion, an atypical antidepressant and tobacco cessation aid, has not been
validated among adolescents. In a study conducted in Austria, the duration of abstinence was
statistically longer among 11 nicotine-dependent adolescents who received buproprion compared to
11 subjects who did not (78 versus 30 days) [138]. However, in a study conducted in the US among
211 adolescent smokers, abstinence rates at 10 and 26 weeks did not statistically differ between those
who received both nicotine patch and buproprion and those who received nicotine patch alone [139].
Similarly, Muramoto et al. showed that buproprion was only associated with a significantly higher
abstinence rate at six weeks but not at 26 weeks among 312 adolescent smokers [140]. Pooled data
from a meta-analysis by Grimshaw et al, failed to demonstrate statistically significant treatment effect
with the use of buproprion [131]. In Muramoto’s study, although generally safe, buproprion use was
associated with more headache and cough versus placebo [140]. Two suicide attempts occurred in the
buproprion group, one in a patient with depression and probable eating disorder. At present, the AHRQ
does not endorse the use of buproprion for tobacco control among adolescents.
Other pharmacotherapeutic agents for tobacco cessation, such as varenicline, a nicotinic receptor
partial agonist, have not been studied among adolescent smokers to date. A preliminary study on the
safety of varenicline was conducted by Faessel et al. [141]. The majority of adverse events were
similar to those found in adults; mild in intensity and included nausea, headache, and vomiting. None
of the adverse events led to drug discontinuation or dose reduction.
Tobacco control among adolescents is however, promising primarily because majority of adolescent
smokers are willing to stop using tobacco. At least 77% of adolescent current smokers have made one
or more serious tobacco cessation attempts [142]. Unfortunately, majority of these attempts are
unplanned and unassisted [143] and hence, only 10% lead to sustained abstinence [144]. This rate of
failed quit attempts, however, exceeds that in adults [143] and adolescent smokers enrolled in tobacco
control programs are twice more likely to succeed than those who are not [129].
7. Tobacco Control among Pregnant Women in the General Population
Factors that are associated with continued tobacco use during pregnancy include lower educational
attainment, long tobacco use history (i.e., at least five years), having a partner who uses tobacco, poor
coping skills, coexisting psychiatric problems, and exposure to secondhand smoke [94,145,146]. There
are also barriers to tobacco cessation that may be unique to women in general that can certainly
influence decision to quit; women in the luteal phase of menstruation tend to be more successful at
tobacco cessation compared to women in the follicular phase [94].
The main strategy used to promote tobacco cessation among pregnant women is also counseling. In
a meta-analysis of 72 randomized controlled trials [147], the estimated pooled risk reduction
associated with any form of counseling during any stage of pregnancy, although low, was significant at
0.94 (95% CI 0.93–0.96). Counseling was also associated with reduced rates of low birthweight
neonates (RR 0.83, 95% CI 0.73–0.95) and preterm births (RR 0.86, 95% CI 0.74–0.98) but not with
neonatal intensive care unit admissions, very low birth weight neonates, stillbirths, perinatal or
neonatal mortality.
Similar counseling models as discussed previously are also utilized among pregnant smokers with
varied success rates. In the same meta-analysis cited previously [147], cognitive behavioral therapy
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was the most studied counseling model with 31 RCTs reviewed (RR 0.95, 95% CI 0.93–0.97),
undoubtedly increasing the over-all risk reduction associated with counseling in general. Strategies that
involved provision of financial incentives (e.g., vouchers amounting to at least $50 [148,149]) to
participants who successfully stopped tobacco use produced the greatest risk reduction (RR 0.76, 95%
CI 0.71–0.81). Although the use of financial motivation is promising, there are currently no studies on
policy implications of undertaking such a strategy at the population level [147].
The use of NRT during pregnancy is controversial primarily due to teratogenicity concerns.
In experimental studies, nicotine was capable of crossing the placenta as well as achieving
concentrations in breast milk 2–3 times higher than in plasma [150]. In animal models, it has been
associated with fetal central nervous system abnormalities, cardiac malformations, pulmonary
hypoplasia, uteroplacental insufficiency, and sudden infant death syndrome [150,151]. In humans,
it has been linked to negative birth outcomes as well. A Danish cohort study among 20,603 pregnant
smokers was conducted to determine the effect of NRT during the first 12 weeks of pregnancy [152].
The prevalence of congenital malformation (especially musculoskeletal defects) was found to be
statistically higher among pregnant women who used NRT compared to those who did not (relative
prevalence ratio 1.61, CI 1.01–2.58). This result should, however, be interpreted with caution as the
proportion of pregnant women who used NRT in this study was small (1.2%). Furthermore, the result
may have been confounded by mismatched risk factors between groups [153]. Pollak et al. showed a
probable link between nicotine exposure and negative birth outcomes when an interim analysis
revealed a higher rate of negative birth outcomes among pregnant smokers who received NRT
compared to those who did not [154]. Gaither et al, in another retrospective study, found that pregnant
smokers who used NRT had twice the risk of having low birth weight babies (OR 1.95, 95% CI:
1.10–3.46) while those who did not use NRT had less than twice the risk (OR 1.31, 95% CI:
0.92–1.87) compared to nonsmokers [155]. The authors postulated that prescription of NRT was
biased toward heavy pregnant smokers who may have also had difficulty with tobacco cessation.
As a result of these studies, nicotine is currently classified as a category D drug (positive evidence
of human fetal risk; maternal benefit may outweigh fetal risk in serious or life-threatening situations).
Despite this, many groups, including the American College of Obstetricians and Gynecologists
(ACOG) [156], recognize its utility especially among high risk pregnant women who fail to stop using
tobacco after counseling. The ACOG states that NRT can be recommended to such women under close
supervision and after comprehensive and informed discussion on the risk of tobacco use and NRT.
This statement emphasizes the fact that the risk of continued tobacco use is evidently greater than the
possible risk of nicotine to the fetus. On the same note, supporters of NRT use during pregnancy also
argue that nicotine levels are similar or even lower in abstinent pregnant women using NRT compared
with those who continue to smoke as nicotine metabolism is increased during pregnancy [151,157].
A pooled risk reduction of NRT for tobacco cessation did not reach statistical significance in a
recent meta-analysis of six RCTs comprising 1,745 pregnant smokers (RR 1.33, 95% CI: 0.93–1.91)
most likely due to low adherence rates to NRT (7.2 to 29%) [158]. Whether this low adherence is
attributed to side effects or other factors was difficult to ascertain as those studies who reported side
effects mentioned only 10–25% adverse events rates (e.g., headache, dizziness, fatigue, heartburn,
nausea, vomiting). Nonetheless, the meta-analysis found no statistically significant difference in the

Int. J. Environ. Res. Public Health 2013, 10

2485

rates of miscarriage, stillbirth, premature birth, or low birthweight deliveries between groups that used
NRT and those that did not.
At present, there are no clinical trials on the use of buproprion or varenicline for tobacco cessation
among pregnant women. Both are classified as category C drugs (animal studies show adverse fetal
effects but no controlled human studies or no animal or human studies; weigh possible fetal risk versus
maternal benefit). Prior studies on the safety of buproprion among depressed pregnant women found
higher rates of spontaneous abortion among those who used buproprion compared to those who did not
(15% versus 4%, p = 0.009) [159] while a later and larger study found no difference in the prevalence
of congenital malformation between these two groups [160]. There are currently no human studies on
varenicline use among pregnant women.
An important issue to address in all tobacco cessation programs undertaken among pregnant women
is whether these interventions lead to a significant postpartum abstinence rate once the main motivation
for tobacco cessation is past [161,162]. Relapse rates range from 67–93% within the first postpartum
year [145]. In the recent meta-analysis by Lumley, the over-all benefit of intervention on abstinence
rates was only significant during pregnancy and up to five months postpartum [147]. These results
imply that women are cognizant of the harms of tobacco use during pregnancy but not of the ill effects
of passive smoking to the baby [145]. Counseling of parents about tobacco cessation during pediatric
visits has been shown to be effective. A study that involved 2,901 mothers of newborns showed that
mothers who received counseling postpartum had higher quit rates and lower relapse rates compared to
those who only received hospital tobacco cessation pamphlets [163]. The same promising results were
seen in other studies [164,165]. Counseling parents about tobacco cessation is currently recommended
by the American Medical Association as part of the routine pediatric visit [166].
Pregnancy offers a special opportunity for clinicians to frequently promote tobacco cessation as
clinic attendances increase significantly during the antepartum and postpartum periods. Despite this,
only half of obstetricians are estimated to address tobacco cessation during each visit and only 28%
discuss actual tobacco cessation interventions [167]. In a meta-analysis by Lumley et al., low intensity
intervention consisting of physician-delivered verbal counseling alone was associated with a
statistically significant risk reduction in continued tobacco use (RR 0.95, 95% CI: 0.93–0.96) [147].
8. Smoking among HIV-Infected Adolescents, Young Adults and Pregnant Women
8.1. Lessons Learned from the General Population
The average number of attempts at tobacco cessation increases with age and the majority of
smokers stop using tobacco after several failed attempts [168]. Furthermore, it is estimated that
mortality rates with tobacco cessation before the age of 35 years are similar to that of
non-smokers [169]. Hence, it is crucial that tobacco cessation interventions are initiated as early as
possible among adolescents, young adults and pregnant women.
Tobacco cessation interventions conducted among adolescents and pregnant women have generally
been successful (Table 5). They mirror strategies in the adult population with the exception of
pharmacotherapy. An appreciable proportion of both adolescents [142] and pregnant women [38] also
desire to quit. Physician-delivered counseling during clinic visits has also been generally successful in

Int. J. Environ. Res. Public Health 2013, 10

2486

these groups [126,147]. This is however an underutilized strategy as only at least half of obstetricians
and pediatricians address tobacco cessation during office visits [127,128,168].
Table 5. Tobacco cessation strategies used in the general population.
Group

Main strategy
Counseling plus
Adults
pharmacotherapy
(NRT/buproprion/varenicline)
Adolescents Counseling
Pregnant
women

Counseling alone or
counseling plus NRT

Treatment effect
OR 1.82 (95% CI: 1.66–2.00) vs. usual care [33]
OR 1.4 (95% CI: 1.20–1.60) vs. pharmacotherapy alone [126]
OR 1.7 (95% CI: 1.30–2.10) vs. counseling alone [126]
OR 2.9 (95% CI: 1.47–4.35) vs. usual care [129]
Counseling alone: RR 0.95 (0.93–0.97) vs. usual care [158]
NRT + Counseling: RR 1.33 (95% CI: 0.93–1.91) vs. usual
care [158]

NRT—nicotine replacement therapy; OR—odds ratio; RR—risk ratio; CI—confidence interval.

8.2. Addressing the Problem
A major obstacle in addressing this issue is the lack of studies on tobacco control among these
vulnerable groups. Nevertheless, studies conducted in the general population can be extrapolated.
The prevalence rates of tobacco use among HIV-infected adolescents, young adults and pregnant
women are also considerably lower than that of older HIV-infected persons and approach that of the
general HIV-uninfected adult population (Table 1). Therefore, addressing the problem of tobacco use
among HIV-infected adolescents, young adults and pregnant women provides an early opportunity to
stop the trajectory of tobacco use at its nascency in the HIV-infected population. HIV infection also
enables clinicians to address tobacco use more frequently among infected adolescents, young adults
and pregnant women as these groups are usually engaged in care and are seen more frequently in clinic
compared to uninfected counterparts. Thus clinicians, including infectious disease providers, need to
actively assess tobacco use among their patients, be knowledgeable about tobacco cessation
interventions, and be able to explain to patients the added risk that tobacco use poses to them above
that of non-HIV-infected smokers. Modern technology (i.e., tablet computers, iPad, mobile devices)
can help in assessing tobacco use. For instance, in our HIV clinics, we conduct a twice yearly risk and
needs assessment using iPads. The assessment includes questions on tobacco use and the patient
answers the questions while waiting for their clinician in the examination room. Once the assessment
is complete, a real-time print-out is then provided to the clinician who will assess the patient. This
practice provides useful information regarding tobacco use, among others, and ensures that risk
behaviors are identified and addressed in a busy clinic setting.
The five A’s for treating tobacco use and dependence (Figure 2) can be used as a first step in
addressing tobacco use with each clinical visit; Ask about tobacco use, Advise to quit, Assess
willingness to quit, Assist with quitting, and Arrange follow-up [126]. This is a strategy endorsed by
the US Department of Health and Human Services to ensure that every patient who uses tobacco is
identified, advised to quit and offered concrete tobacco cessation intervention. Among adolescents,
a sixth A is usually included, to enable clinicians to Anticipate the risk of tobacco use among
adolescent nonsmokers by assessing peer and parental influence and discussing possibility of tobacco
initiation. Anticipation of this risk should be extended to all nonsmokers regardless of age.
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Figure 2. The 5 A’s of treating tobacco use and dependence.

Adapted from: Fiore MC, Jaen CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update.
U.S. Department of Health and Human Services 2008. Available at: http://www.ncbi.nlm.nih.gov/books/
NBK63952/.

9. Conclusions
HIV-infected persons have improved life expectancy in the HAART era, however, mortality rates
remain higher than the general population and early-onset multimorbidity with non-AIDS defining
illnesses is characteristic. Behavioral factors certainly contribute to this excess mortality and morbidity
risk. The prevalence of tobacco use among HIV-infected persons is up to threefold higher than the
general population. Due to shared pathogenic mechanisms with HIV infection, tobacco use magnifies
the inherent risk of cardiovascular/peripheral vascular disease, ischemic stroke, lung and cervical
cancer, and osteoporosis that HIV-infected persons have.
HIV-infected adolescents, young adults and pregnant women are important targets for effective
tobacco control programs. The cardiovascular and pulmonary risks associated with tobacco use are
established early among adolescent smokers. Tobacco use during pregnancy also leads to a number of
preventable maternal and fetal risks. At present, studies on effective tobacco control among these
groups are lacking.
Addressing tobacco use early among HIV-infected adolescents, young adults, and pregnant women
also provides a doable and practical preemptive strike against the tobacco epidemic in the HIV-infected
adult population. Since these groups are usually engaged in HIV-related care, providers can repeatedly
offer tobacco cessation counseling and follow-up on failed tobacco cessation attempts. Thus, it is of
fundamental importance that HIV care providers actively assess tobacco use among their clinic
population and that tobacco control strategies are routinely and consistently implemented in the
outpatient clinic.
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